Recon: Merck pens $1.4B deal to acquire Imago to bolster bone marrow disease pipeline; Teva names former Sandoz head as next CEO
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy